MedTrace Logo

AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC

NCT05632328 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-20

No results posted yet for this study

Summary

The goal of this research study is to asses the safety and efficacy of the combination of AGEN1423 and Botensilimab with or without chemotherapies, gemcitabine and nab-paclitaxel, for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC) which has progressed after at least one previous line of cancer therapy.

The names of the study drugs involved in this study are:

* AGEN1423
* Botensilimab

Participants will receive study treatment for about 2 years and will be followed for 1 year after.

Conditions

Interventions

DRUG

AGEN1423

via IV, dosage per protocol, once every 2 weeks for up to 8 weeks

DRUG

Botensilimab

via IV, dosage per protocol, once evert 2 weeks, up to 2 years

DRUG

Gemcitabine

per standard care

DRUG

Nab-paclitaxel

per standard care

Sponsors & Collaborators

Principal Investigators

  • Bruno Bockorny, MD · Beth Israel Deaconess Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2026-05-01
Completion
2027-04-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05632328 on ClinicalTrials.gov